Trading status Status de
  • Prices realtime
    • Indizes
      • UC DAX
      • UC MDAX
      • UC TECDAX
      • UC DJI
      • UC ESTOXX
      • UC NASQAD 100
    • Shares
    • ETFs & FUNDS
    • Bonds
    • Crypto
  • Screen markets
    • Stock screener
    • Certifcate Screener
    • ETF Screener
    • Fund Screener
    • Bond screener
  • Trading ideas
    • risk indices
      • risk indices
      • EU Intraday
      • EU Long Term
      • US Intraday
      • US Longterm
    • New on gettex
      • New listings stocks
      • New listings bonds
      • New intraday certificates
    • Blog
    • Newsletter
    • Watchlist
    • Support
  • Trading
    • Trading Calendar
    • Extended trading hours
    • Listing on demand
    • Announcements
    • Quality Reports
    • Delayed Data
    • Regulations
    • Become a Trade Participant
    • Cancellations
  • About Gettex
    • FAQs
    • Press
    • Partners
    • Committees
    • Career
    • Service & Contact
  • Why gettex

News overview

  • «
  • ‹
  • …
  • 4399
  • 4400
  • 4401
  • …
  • ›
  • »

2026-04-21

Odd Lots: QXO′s Brad Jacobs on His Big Insulation Bet (Podcast)

2026-04-21

Karyopharm′s Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

2026-04-21

Valmont (VMI) Q1 2026 Earnings Call Transcript

2026-04-21

Western Alliance (WAL) Q4 2025 Earnings Transcript

2026-04-21

Zurn Elkay (ZWS) Q4 2025 Earnings Transcript

2026-04-21

Pegasystems (PEGA) Q3 2025 Earnings Transcript

2026-04-21

KBRA Releases Research – Implications for Global Shipping

2026-04-21

Le Pen′s Energy Plan for France Called a ′Disaster′ by Engie CEO

2026-04-21

BioInvent International: BioInvent to Present Data of BI-1808 Plus KEYTRUDA in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting

2026-04-21

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

2026-04-21

SMG Annual General Meeting 2026: all motions and dividend of CHF 0.82 per share approved

2026-04-21

Sinopharm Group Subsidiary Sinopharm Consistent 1Q Net Profit RMB287M, Down 12.4% YoY

  • «
  • ‹
  • …
  • 4399
  • 4400
  • 4401
  • …
  • ›
  • »

Preset online depot

Favorites: Zertifikate-Finder FAQs Newsletter
Realtimeprices 18/Jun/2026 10:00:49
Tradingtime Mo-Fr: 7:30-23 h
Certificates 8:00-22 h
  • Imprint
  • Legal notice
  • Data protection
  • Contact
  • Cookies